Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale
Расширение временного окна для внутривенного введения тенектеплазы у пациентов с инсультом вследствие окклюзии дистальных сосудов среднего калибра: протокол исследования и его обоснование
2026-04-13
SCID: 54.1/9n9mjht3
Discuss with AI
distal medium vessel occlusionextended treatment windowintravenous tenecteplasemodified Rankin Scalesymptomatic intracerebral haemorrhage
Figures from the paper
Abstract (AI)
BACKGROUND: The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5-24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging, intravenous tenecteplase (TNK) thrombolysis is safe and can significantly improve patient outcomes in cases where endovascular thrombectomy is not feasible. However, it is currently unknown whether intravenous TNK thrombolysis beyond 4.5 hours can improve the outcomes of subjects with distal medium vessel occlusion (MeVO). OBJECTIVE: To determine the safety and effectiveness of extended window TNK thrombolysis for MeVO stroke. METHODS AND DESIGN: Extending the Time Window for Intravenous TNK in Patients with Distal Medium Vessel Occlusions Stroke (TNK-MeVO) is a prospective, randomised, controlled, multicentre and open-label study with blinded outcome assessment. Up to 560 eligible subjects will be randomised 1:1 to receive TNK thrombolysis or standard medical management in over 40 comprehensive stroke centres across China. OUTCOMES: The primary endpoint is the rates of modified Rankin Scale score of 0-1 at 90 days. Safety endpoints include symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days. CONCLUSIONS: TNK-MeVO trial is designed to provide robust evidence on whether TNK thrombolysis is safe and effective for acute MeVO stroke presenting 4.5-24 hours of symptom onset. TRIAL REGISTRATION NUMBER: NCT06559436.
Key Findings
1
Key safety endpoints are symptomatic intracerebral hemorrhage within 24 hours and mortality at 90 days.
2
The TNK-MeVO trial addresses whether intravenous tenecteplase beyond 4.5 hours improves outcomes in distal medium vessel occlusion stroke.
3
The primary efficacy endpoint is the proportion of patients achieving a modified Rankin Scale score of 0–1 at 90 days.
4
The study is a prospective, randomized, controlled, multicenter, open-label trial with blinded outcome assessment across more than 40 Chinese comprehensive stroke centers.
5
Up to 560 eligible patients will be randomized 1:1 to tenecteplase thrombolysis or standard medical management for symptoms presenting 4.5–24 hours after onset.
Research Object
Patients with acute distal medium vessel occlusion (MeVO) stroke presenting 4.5–24 hours after symptom onset
Research Subject
Safety and effectiveness of extended-window intravenous tenecteplase thrombolysis, including functional outcome, symptomatic intracerebral haemorrhage, and mortality
Publication Details
Publication Date
2026-04-13
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest